DOI: 10.1055/s-00000133

Gastroenterologie up2date

Referenz

Joensuu H, Eriksson M, Sundby-Hall K. et al.
Survival Outcomes Associated With 3 Years vs. 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors: An Analysis of a Randomized Clinical Trial After 10-Year Follow-up.

JAMA Oncol 2020;
6: 1241-1246

Bibliographische Angaben herunterladen

Aufrufen in:
Aufrufen in: